Latest Breaking News On - Patrick roth - Page 3 : comparemela.com

Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage repair (DDR) and reverse the poor prognosis for patients with GBM. This multicenter clinical trial launched in the US, Spain and Switzerland is following the preclinical GBM data presented at the annual American Association for Cancer Research 2023 meeting (AACR 2023: Abstract #6185) in Orlando, Florida. LAUSANNE, Switzerland, May 17, 2023 /PRNewswire/ Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards ofcare to cure cancer and infectious diseases, today announced the start of its open-label Phase 1/2 study evaluating Debio 0123, a brain-penetrant and highly selective WEE1 inhibitor, in combination with temozolomid

United statesPatrick rothVictor rodriguez freixinosJordi rodon ahnertMd anderson cancer centerAmerican association for cancer researchUniversity hospital zrichHead of communicationsAmerican associationCancer researchCancer centerAssociate medical directionUniversity hospitalDamage repairGlioblastomas gbm are among the most aggressive and lethal tumors of central nervous system witha 5 year survival rate only 6 8 debiopharm is combining its potentRain penetrant wee1 inhibitor debio 0123 with standard of care soc therapy hopes to hinder dna damage repair ddr and reverse the poor prognosis for patients gbm this multicenter clinical trial launched in us